drugset / Trial / NCT01898377
Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children
NaSingle-groupOpen-labelTreatment
Summary
In this study we will combine mycophenolate mofetil and imatinib mesylate to treat steroid-refractory sclerotic/fibrotic type chronic graft-versus-host disease (GVHD) to see the response rate and to find the safety of combination.
Timeline
- Start
- 2013-08
- Primary completion
- 2018-02-14
- Completion
- 2018-02-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 260 mg/m2 | — |
| Subject | Mycophenolate Mofetil | Small molecule | 15 mg/kg | Oral |
| Subject | Mycophenolate Mofetil | Small molecule | 20 mg/kg | Oral |